Italia markets closed
  • FTSE MIB

    20.648,85
    +295,87 (+1,45%)
     
  • Dow Jones

    28.725,51
    -500,10 (-1,71%)
     
  • Nasdaq

    10.575,62
    -161,89 (-1,51%)
     
  • Nikkei 225

    25.937,21
    -484,84 (-1,83%)
     
  • Petrolio

    79,74
    -1,49 (-1,83%)
     
  • BTC-EUR

    19.748,65
    -230,24 (-1,15%)
     
  • CMC Crypto 200

    443,49
    +0,06 (+0,01%)
     
  • Oro

    1.668,30
    -0,30 (-0,02%)
     
  • EUR/USD

    0,9801
    -0,0018 (-0,19%)
     
  • S&P 500

    3.585,62
    -54,85 (-1,51%)
     
  • HANG SENG

    17.222,83
    +56,96 (+0,33%)
     
  • Euro Stoxx 50

    3.318,20
    +39,16 (+1,19%)
     
  • EUR/GBP

    0,8781
    -0,0041 (-0,46%)
     
  • EUR/CHF

    0,9669
    +0,0095 (+1,00%)
     
  • EUR/CAD

    1,3549
    +0,0120 (+0,89%)
     

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

·1 minuto per la lettura
Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York. Management will be available June 8th for 1x1 meetings.

A live webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com